Search details
1.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol
; 15(7): 747-56, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24794243
2.
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Clin Cancer Res
; 22(23): 5747-5754, 2016 Dec 01.
Article
in English
| MEDLINE | ID: mdl-27189162
3.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol
; 32(29): 3212-20, 2014 Oct 10.
Article
in English
| MEDLINE | ID: mdl-25199759
4.
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.
Breast Care (Basel)
; 6(4): 279-283, 2011.
Article
in English
| MEDLINE | ID: mdl-22164126
Results
1 -
4
de 4
1
Next >
>>